Drug Profile
Amphotericin B - Jina Pharmaceuticals/Intas Pharmaceuticals
Alternative Names: Amfy; Nanosomal amphotericin BLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Intas Pharmaceuticals; Jina Pharmaceuticals
- Class Antifungals; Antiprotozoals; Antipyretics; Macrolides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Mycoses
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Mycoses in Unknown (PO)
- 22 Oct 2015 Intas Pharmaceuticals and Jina Pharmaceuticals collaborated in the development of Nanoaqualip™ technology
- 27 Aug 2015 Launched in Mycoses in India (IV) before August 2015